Study guide

6.11 Hematologic, Immunologic, and Oncology Supportive Care

PEBC Pharmacist Evaluating Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape

1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation

2 Chapter 2: Pharmaceutics & Drug Delivery Systems

2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence

3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics

3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application

4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics

4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics

5 Chapter 5: Pathophysiology & Clinical Assessment

5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing

6 Chapter 6: Pharmacotherapy & Minor Ailments

6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine

7 Chapter 7: Special Populations & Applied Therapeutics

7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment

8 Chapter 8: Prescription Processing, Calculations & Compounding

8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation

9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics

9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health

10 Chapter 10: Evidence Appraisal, Safety & Practice Management

10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada

11 Chapter 11: Patient Care Process, Communication & Collaborative Practice

11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care

12 Chapter 12: Medication Administration, Devices & Expanded Scope

12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation

13 Chapter 13: Pharmacy Management, Finance & Practice Leadership

13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety

6.11 Hematologic, Immunologic, and Oncology Supportive Care

Key Takeaways Explain This Topic AI

Iron deficiency anemia is confirmed by a low ferritin; oral iron is best absorbed as a single daily or alternate-day dose taken on an empty stomach with a source of vitamin C.

Vitamin B12 deficiency must be corrected before or alongside folate, because folate alone corrects the anemia while allowing irreversible neurological damage to progress.

Anaphylaxis is treated with intramuscular epinephrine into the anterolateral thigh; antihistamines and corticosteroids are adjuncts that never replace it.

Live vaccines are contraindicated in significantly immunosuppressed patients, including solid organ transplant recipients on maintenance immunosuppression.

Febrile neutropenia — a single temperature of 38.3 degrees Celsius or 38.0 sustained for an hour with an absolute neutrophil count below 0.5 x 10^9/L — is a medical emergency requiring antibiotics within one hour.

Last updated: August 2026

6.11 Hematologic, Immunologic, and Oncology Supportive Care

Exam Focus: These topics appear in the Pharmacotherapeutics subcategory and in Appendix 1 of the PEBC syllabus. High-yield items involve interpreting a complete blood count, recognising an oncologic or immunologic emergency, and counselling an immunosuppressed patient.

The Anemias

Classify first by mean corpuscular volume (MCV), then confirm with iron studies and vitamin levels.

Type MCV Confirmatory findings Treatment

Iron deficiency Low (microcytic) Ferritin low, transferrin saturation low, total iron-binding capacity high Oral iron; investigate the source of blood loss

Anemia of chronic disease Normal or low Ferritin normal or high, transferrin saturation low Treat the underlying disease

Vitamin B12 deficiency High (macrocytic) Low B12, raised methylmalonic acid and homocysteine Cyanocobalamin oral high dose or intramuscular

Folate deficiency High (macrocytic) Low red cell folate, raised homocysteine, normal methylmalonic acid Folic acid, after excluding B12 deficiency

Iron therapy counselling. Elemental iron content differs sharply between salts — ferrous fumarate 300 mg contains about 100 mg elemental iron, ferrous sulfate 300 mg about 60 mg, and ferrous gluconate 300 mg about 35 mg. Current evidence supports a single daily dose or alternate-day dosing , because more frequent dosing raises hepcidin and reduces fractional absorption. Take on an empty stomach with a vitamin C source; separate from calcium, antacids, proton pump inhibitors, tetracyclines, quinolones, and levothyroxine by at least two hours. Warn about black stools (expected) and constipation, and continue therapy for three months after hemoglobin normalises to refill stores.

Vitamin B12 before folate. Both correct the megaloblastic anemia, but only B12 replacement halts subacute combined degeneration of the spinal cord. Giving folate alone to a B12-deficient patient masks the hematologic sign while the neurological injury becomes permanent. Long-term metformin and proton pump inhibitor use are common contributors to B12 deficiency.

Drug-induced hematologic disorders to recognise: clozapine and carbamazepine (agranulocytosis), linezolid and valproate (thrombocytopenia), heparin (heparin-induced thrombocytopenia, a prothrombotic state despite the falling platelet count), methotrexate and trimethoprim (megaloblastic change), and dapsone, primaquine, nitrofurantoin, and sulfonamides (hemolysis in glucose-6-phosphate dehydrogenase deficiency).

Hypersensitivity and Anaphylaxis

Distinguish a true immunoglobulin E-mediated allergy from an intolerance. Rash alone years earlier is not the same as urticaria with angioedema and bronchospasm, and mislabelled penicillin allergy drives the use of broader, more toxic, and less effective antibiotics.

Anaphylaxis management is a fixed sequence:

Intramuscular epinephrine into the anterolateral thigh , 0.01 mg/kg to a maximum of 0.5 mg, repeated every 5 to 15 minutes as needed. There is no absolute contraindication.

Call emergency services; position the patient supine with legs elevated unless breathing is compromised.

Adjuncts only after epinephrine: antihistamines for cutaneous symptoms, inhaled beta-2 agonist for bronchospasm, corticosteroids historically used for biphasic reactions.

Counsel every auto-injector user to carry two devices, demonstrate the technique with a trainer, check expiry dates, and seek emergency care after any use because of biphasic reactions. Patients on beta-blockers may respond poorly to epinephrine and can require glucagon.

Desensitisation allows a needed drug to be given despite immunoglobulin E-mediated allergy, is performed under specialist supervision, and confers only temporary tolerance that is lost once therapy is interrupted.

Transplant Immunosuppression and Autoimmune Disease

Solid organ transplant maintenance usually combines a calcineurin inhibitor (tacrolimus or cyclosporine), an antimetabolite (mycophenolate or azathioprine), and a corticosteroid .

Tacrolimus and cyclosporine are narrow-therapeutic-index CYP3A4 substrates. Grapefruit juice, azole antifungals, macrolides, and diltiazem raise levels; rifampin, phenytoin, carbamazepine, and St. John's wort lower them and can cause graft rejection.

Adverse effects include nephrotoxicity, tremor, hypertension, hyperkalemia, and new-onset diabetes; cyclosporine additionally causes gingival hyperplasia and hirsutism.

Prophylaxis typically includes trimethoprim-sulfamethoxazole for Pneumocystis jirovecii and valganciclovir for cytomegalovirus in at-risk recipients.

Live vaccines are contraindicated after transplantation. Inactivated vaccines, including annual influenza, are recommended, ideally completed before transplantation.

Systemic lupus erythematosus is managed with hydroxychloroquine as background therapy for nearly all patients, with corticosteroids, immunosuppressants, and belimumab layered by organ involvement. Sun protection is a therapeutic measure. Drug-induced lupus, classically from hydralazine, procainamide, isoniazid, or minocycline, spares the kidneys and central nervous system and resolves after the drug is stopped.

Oncology Supportive Care

Pharmacists rarely select cytotoxic regimens on this examination, but they are expected to manage the consequences.

Complication Recognition Management

Febrile neutropenia One temperature of 38.3 degrees Celsius, or 38.0 sustained one hour, with absolute neutrophil count below 0.5 x 10^9/L Emergency : broad-spectrum antibiotics within one hour

Chemotherapy-induced nausea and vomiting Acute, delayed, anticipatory, breakthrough Prophylaxis matched to emetogenic risk: 5-HT3 antagonist, neurokinin-1 antagonist, dexamethasone, olanzapine

Mucositis Painful oral ulceration Bland rinses, good oral care, analgesia; avoid alcohol-containing mouthwash

Tumour lysis syndrome High potassium, phosphate, and urate; low calcium; acute kidney injury Hydration, allopurinol or rasburicase

Cancer pain Persistent, often mixed Scheduled long-acting opioid with breakthrough dosing, plus adjuvants; constipation prophylaxis from day one

Never treat a fever in a neutropenic patient as a minor ailment. Counsel patients on cytotoxic therapy to report fever, bleeding, or new bruising immediately, to handle oral cytotoxic tablets without crushing or splitting, and to follow safe handling of body fluids for the period specified for their regimen.